Despite continuous efforts to improve outcome of primary treatment for Prostate cancer (PCa), a considerable number of patients treated with radiotherapy will experience biochemical recurrence (BCR) defined as a prostate specific antigen (PSA) of 2 ng/mL + nadir. This evidence concerns the gene KLK3 and prostate cancer.